RT Journal Article SR Electronic T1 The Harvard-Emory ECG Database JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2024.09.27.24314503 DO 10.1101/2024.09.27.24314503 A1 Koscova, Zuzana A1 Li, Qiao A1 Robichaux, Chad A1 Moura Junior, Valdery A1 Ghanta, Manohar A1 Gupta, Aditya A1 Rosand, Jonathan A1 Aguirre, Aaron A1 Hong, Shenda A1 Albert, David E. A1 Xue, Joel A1 Parekh, Aarya A1 Sameni, Reza A1 Reyna, Matthew A. A1 Westover, M. Brandon A1 Cliford, Gari D. YR 2024 UL http://medrxiv.org/content/early/2024/10/01/2024.09.27.24314503.abstract AB The Harvard-Emory ECG Database (HEEDB) is a large collection of 12-lead electrocardiogram (ECG) recordings, developed through a collaboration between Harvard University and Emory University. The database consists of 10,608,417 unique ECG recordings from 1,818,247 patients from Massachusetts General Hospital (MGH) and 1,452,964 recordings from 552,481 patients from Emory University Hospital (EUH) collected in clinical settings as part of routine patient care since the early 1990s. Continuously updated with new data, the recordings consist of 10-second, 12-lead ECGs sampled at 250 and 500 Hz, and stored in WFDB format. Future updates will include demographic information such as age, sex, race, and ethnicity. Additionally, 12SL annotations–encompassing ECG diagnoses, morphology, and rhythms–are available for 10,471,531 recordings from MGH and 1,268,277 recordings from EUH. Shortly, ICD-9/10 codes, CPT codes, and medication history will also be made publicly available.Competing Interest StatementM.B.W. is a co-founder, scientific advisor, and consultant to Beacon Biosignals and has a personal equity interest in the company. D.E.A. is the founder and Chief Medical Officer of AliveCor Inc. and holds personal equity in the company. J.X. is a research fellow at Alivecor Inc. and also holds personal equity in the company. G.D.C. holds significant stock in AliveCor Inc. The other authors report no competing interests.Funding StatementPublication of HEEDB is supported by a grant (R01HL161253) from the National Heart Lung and Blood Institute (NHLBI) of the NIH. Publication of the HEEDB is also supported by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under NIH grant number R01EB030362, and an unrestricted funds from Emory University. Q.L., M.R. and G.D.C. are supported in part by unrestricted funding from AliveCor Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Emory University gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced are available online with credentialed access at https://bdsp.io/content/heedb/1.0/ and shortly will be available publicly. https://bdsp.io/content/heedb/1.0/